Lineage-Specific Viral Hijacking of Non-Canonical E3 Ubiquitin Ligase Cofactors in the Evolution of Vif Anti-APOBEC3 Activity

Joshua R. Kane1,2, David J. Stanley3, Judd F. Hultquist1,2,4,5, Jeffrey R. Johnson1,2,5, Nicole Mietrach6, Jennifer M. Binning3, Stefán R. Jónsson6, Sarah Barelier7, Billy W. Newton1,2,5, Tasha L. Johnson1,2,5, Kathleen E. Franks-Skiba1,2, Ming Li4, William L. Brown4, James S. Fraser7, Reuben S. Harris4, Valgerður Andrésdóttir6, John D. Gross3,+, and Nevan J. Krogan1,2,5,+

1University of California, San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA 94158 2University of California, San Francisco, California Institute for Quantitative Biosciences, QB3, San Francisco, CA 94158 3University of California, San Francisco, Department of Pharmaceutical Chemistry, San Francisco, CA 94158 4University of Minnesota, Department of Biochemistry, Molecular Biology and Biophysics, Institute for Molecular Virology, Minneapolis, MN 55455 5J. David Gladstone Institutes, Gladstone Institute of Virology and Immunology, San Francisco, CA 94158 6University of Iceland, Institute for Experimental Pathology, Keldur, 112 Reykjavik, Iceland 7Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA 94158

SUMMARY

HIV-1 encodes the accessory protein Vif, which hijacks a host Cullin-RING ubiquitin ligase (CRL) complex as well as the non-canonical cofactor CBFβ, to antagonize APOBEC3 antiviral proteins. Non-canonical cofactor recruitment to CRL complexes by viral factors, to date, has only been attributed to HIV-1 Vif. To further study this phenomenon, we employed a comparative approach combining proteomic, biochemical, structural, and virological techniques to investigate Vif complexes across the lentivirus genus, including primate (HIV-1, SIVmac) and non-primate (FIV, BIV, and MVV) viruses. We find that CBFβ is completely dispensable for the activity of non-primate lentiviral Vif proteins. Furthermore, we find that BIV Vif requires no cofactor, and that MVV Vif requires a novel cofactor, Cyclophilin A (CYPA), for stable CRL complex formation and anti-APOBEC3 activity. We propose modular conservation of Vif complexes

*Co-corresponding authors: nevan.krogan@ucsf.edu, john.gross@ucsf.edu.

AUTHOR CONTRIBUTIONS

JRK conceived the project with NJK and RSH, performed affinity purifications, scored mass spectrometry data, created stable cell lines, performed CsA assays, knockdown assays, Jurkat nucleofection experiments. DJS performed in vitro reconstitution of Vif-CRL complexes, ubiquitylation assays. JFH performed single-cycle HIV infectivity assays, assisted with Jurkat nucleofection experiments. JRJ, BWN, TLJ, KEFS performed MS sample preparation, machine runs, data searching. NM, SRJ performed MVV virology assays. JMB generated SAXS envelopes of Vif-CRL5 complexes. SB performed NMR experiments. ML purified A3 proteins for in vitro ubiquitylation assays. WLB sequenced MVV proviral sequences for hypermutation assays. JRK wrote the manuscript with assistance from JFH and NJK. JRK, DJS, JFH, JMB, SB, JSF, RSH, VA, JDG, and NJK edited the manuscript.

Publisher’s Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
allows for potential exaptation of novel functions through the acquisition of non-CRL associated host cofactors while preserving anti-APOBEC3 activity.

**Graphical Abstract**

![Graphical Abstract](image)

**INTRODUCTION**

Viruses must overcome host challenges to replicate successfully in an infected host. These challenges include not only the mechanics of viral entry, genetic replication, assembly, and budding, but also a variety of host defined replication barriers, both innate and adaptive. During productive infection, viral proteins rewire the host cell through series of protein-protein interactions (PPIs) to promote viral replication. Systematic and unbiased mapping of these host-pathogen interactions can yield novel information concerning both viral biology and the endogenous functions of hijacked host factors.

An effective method for mapping host-pathogen interactions involves affinity purification of epitope-tagged viral proteins from host cells followed by mass spectrometry (AP-MS) to identify interacting host factors. This approach has been used to map global host-pathogen PPIs for HIV-1 (Jäger et al., 2012a), Herpes (Davis et al., 2015), and Hepatitis C (Ramage et al., 2015), as well as to study the PPIs of individual viral proteins in HPV (Tan et al., 2012; White et al., 2012a, 2012b), influenza (York et al., 2014), and picornaviruses (Greninger et al., 2012). Historically, these types of proteomic analyses have focused on a single virus or closely related sets of viruses, and typically from the same (human) host.

In this study, we devised a strategy for the systematic, comparative analysis of host-pathogen PPIs focusing on the well-characterized lentivirus genus to analyze the complexes formed by representative Vif proteins from different lentiviral clades, including that of human immunodeficiency virus 1 (HIV-1). HIV-1 Vif is required for pathogenesis *in vivo* and serves as the virus’ defense against host antiviral APOBEC3 (A3) proteins. In the
The absence of Vif, members of the A3 family of restriction factors package into budding virions where they interfere with reverse transcription and induce lethal G-to-A hypermutation in the viral cDNA (Harris et al., 2003; Iwatani et al., 2007; Mangeat et al., 2003; Zhang et al., 2003). HIV-1 Vif overcomes this replication block by acting as an adapter between the A3 proteins and an endogenous ubiquitin ligase complex that catalyzes poly-ubiquitylation of the A3 proteins, resulting in their subsequent proteasomal degradation (Hultquist et al., 2011; Sheehy et al., 2002, 2003; Yu et al., 2003).

The HIV Vif E3 ligase complex is composed of the endogenous CRL5 members, including CULLIN-5 (CUL5), ELONGIN B (ELOB), ELONGIN C (ELOC), and RING-box protein 2 (RBX2), but also requires the additional Vif-dependent recruitment of a non-canonical cofactor, core binding factor beta (CBFβ) (Guo et al., 2014; Jäger et al., 2012b; Zhang et al., 2012). CBFβ normally forms a heterodimer with RUNX family of transcription factors, serving to both stabilize RUNX steady-state levels and to enhance DNA-binding affinity (Huang et al., 2001; Tahirov et al., 2001). Recruitment of CBFβ serves to stabilize HIV-1 Vif and is required for HIV-1 Vif A3 degradation activity in vivo (Hultquist et al., 2012; Jäger et al., 2012b; Kim et al., 2013; Miyagi et al., 2014; Zhang et al., 2012). Recent work has shown that this recruitment alters endogenous RUNX activity through competitive binding of HIV-1 Vif to CBFβ, potentially to the benefit of the virus (Kim et al., 2013; Klase et al., 2014).

We chose to focus our comparative study on Vif for three primary reasons. First, a Vif protein is expressed in four of the five major lentiviral clades, each of which is known to mediate the proteasomal degradation of the cognate host A3 proteins (LaRue et al., 2010). Second, unlike ubiquitously conserved lentiviral components such as Gag or Pol, Vif is not known to be required for the mechanics of viral replication and thus is potentially less constrained over the course of virus evolution. Third, while the mechanism of HIV-1 Vif-mediated A3-degradation is well characterized, little is known about the requirements for Vif proteins from other clades. While recruitment of ELOC is assumed based on the conserved BC-box motif, it is unknown if these Vif proteins recruit the same core E3 ligase complex and if they require recruitment of a noncanonical E3 ligase component such as CBFβ. In fact, recent work has suggested that other factors may be required for Vif stability and function in non-primate lentiviruses (Ai et al., 2014; Zhang et al., 2014a, 2014b).

Here, we report a comparative proteomics strategy for the study of orthologous host-pathogen PPIs, which we subsequently use to analyze the complexes formed by representative Vif proteins from different lentiviral clades, including primate lentiviruses (HIV-1 and simian immunodeficiency virus macaque, SIVmac), bovine immunodeficiency virus (BIV), feline immunodeficiency virus (FIV), and the ovine-tropic maedi visna virus (MVV). We find that while all lentiviral Vif orthologs can hijack the CRL5 complex in human cells, only primate lentiviral Vif proteins hijack CBFβ and require it for A3 degradation. While one non-primate lentiviral Vif, from BIV, appears to operate independently of any non-canonical cofactors, another Vif, from MVV, requires a novel non-canonical cofactor, cyclophilin A (CYPα), for in vitro reconstitution and in vivo A3-degrading activity. These results demonstrate an unexpected mechanistic flexibility in viral rewiring of the host cell despite the maintenance of a conserved activity. They furthermore...
suggest a modular conservation of host-pathogen interactions whereby novel PPIs may be formed with novel partners to serve the same functional purpose yet with potentially new orthogonal roles. We predict that the use of modular conservation to allow for mechanistic flexibility may be a generalizable model for viral protein evolution.

RESULTS

Divergent Vif Proteins Interact with Conserved Host CRL Complex

All known lentiviruses express a Vif protein except for equine infectious anemia virus and the extinct rabbit endogenous lentivirus RELIK (Katzourakis et al., 2007; Kawakami et al., 1987). The Vif protein from each lentivirus is known to perform at least one conserved function, degradation of the restrictive A3 proteins from the cognate host (Hultquist et al., 2011; LaRue et al., 2010; Sheehy et al., 2003; Yu et al., 2003). Despite this conservation in function, the primary sequence of these proteins is highly divergent, sharing no more than 25% identity of alignable residues between any pair (Figures 1A, S1A). The only obvious conserved motif is the ELOC-binding BC-box, which is known to be essential for A3 degradation. This has lead to the hypothesis that each Vif protein mediates A3 degradation by recruitment of the same CRL5 complex, but a systematic characterization of each lentivirus’ Vif complex had not previously been carried out.

In order to determine which host factors are physically bound to Vif proteins across the lentivirus phylogeny, we employed an unbiased proteomic approach using AP-MS to study five divergent Vif proteins from MVV, BIV, FIV, SIVmac, and HIV-1 (Table S1). Affinity tags comprising 2xStrep or 3xFlag were fused to either the amino (N-) or carboxy (C-) terminus of the Vif proteins, and tagged Vif constructs were either transiently expressed in HEK293T cells or used to make stable, doxycycline-inducible Jurkat T-cell lines (Figure 1B). Tagged Vif proteins were affinity purified and eluates subjected to SDS-PAGE and silver staining (Figure 1C), then analyzed by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) to identify co-purified host factors (Jäger et al., 2012a). Putative interactions identified by AP-MS were scored using the significance analysis of interactome (SAINT) algorithm (Choi et al., 2011), and interactions with a SAINT probability score ≥0.9 in at least one Vif dataset were included (Table S2). Prey scores were then organized by cell line and hierarchically clustered by correlation (Figure S2A). Within this dataset, we observe expected interactions with CRL complex proteins, including CUL2, CUL5, ELOB, ELOC, RBX2 and RBX1, strongly suggesting a generally conserved mechanism for A3 proteasomal degradation among Vif proteins (Figure 1D). We observe within the dataset a terminus-specific effect on Vif-CULLIN specificity between CUL2 and CUL5, particularly with the non-primate lentivirus Vif proteins (Figure 1D, E, Figure S2B–D).

The association of Vif with CBFβ was only observed for primate lentivirus Vif proteins (SIVmac, HIV-1) in the AP-MS datasets for both HEK293T cells and Jurkat T-cells (Figure 1D), an observation confirmed by immunoblot analysis (Figure 1E, S2B). To test if Vif proteins not observed to physically interact with CBFβ were still functionally regulated by the factor, we employed a single-cycle HIV infectivity assay testing for Vif-mediated A3 degradation in the presence and absence of CBFβ (Figure 2A). We observed that HIV-1 and
SIVmac require CBFβ for Vif-mediated rescue of HIV infectivity from A3 restriction (Figure 2B, C), as previously reported (Hultquist et al., 2012; Jäger et al., 2012b). Conversely and consistent with the AP-MS results, the non-primate lentivirus Vif proteins (MVV, BIV, FIV) showed no dependence on CBFβ for activity, eliciting equivalent ability to rescue HIV infectivity from A3 restriction both in the presence and in the absence of CBFβ (Figure 2D–F). This finding agrees with recently reported data for MVV, BIV, and FIV Vif proteins (Ai et al., 2014; Han et al., 2014; Zhang et al., 2014a, 2014b).

**BIV Vif Assembles a CRL Complex Without a Non-Canonical Cofactor**

Having observed no dependence of the non-primate Vif proteins on CBFβ for the in vivo degradation of cognate A3 proteins, we asked whether the corresponding Vif-CRL complexes might reconstitute in vitro without CBFβ or other additional host factors. We have shown previously that HIV Vif requires CBFβ to form a stable complex with ELOB and ELOC and CUL5/RBX2 in vitro (Figure 2G, H; Jäger et al., 2012b). Unexpectedly, BIV Vif formed a stable trimer with ELOB and ELOC alone with no other cofactors required as assessed by size-exclusion chromatography (Figure 2G). This trimer readily associated with the CUL5/RBX2 scaffold (Figure 2G, H) to form an active complex capable of polyubiquitylating Myc-tagged bovine A3Z3 (BtA3Z3) (Figure 2I). The level of ubiquitylation was comparable to HIV-1 Vif-CRL mediated ubiquitylation of Myc-tagged human A3F CTD domain (HsA3F-CTD) (Figure 2I). Reconstitution of active BIV Vif-CRL5 complex thus confirmed that only the endogenous CRL5 complex is required for BIV Vif activity, in stark contrast with the primate lentiviral Vif proteins that require the additional recruitment of CBFβ for equivalent activity.

**CYPA Implicated as an MVV Vif Host Cofactor**

While we successfully reconstituted the BIV Vif-CRL5 complex without a non-canonical host cofactor, we were unable to do so with the other non-primate lentiviral Vif complexes (MVV; FIV). Both MVV Vif-ELOB-ELOC and FIV Vif-ELOB-ELOC complexes aggregated during size-exclusion chromatography after purification, mimicking behavior observed with HIV-1 Vif in the absence of CBFβ (Figure S3A, B; Kim et al., 2013). These data suggested additional host cofactors are required for stable complex formation of the MVV Vif and FIV Vif CRL5 complexes.

To identify the missing components of the non-primate Vif-CRL5 complexes, we utilized a double affinity-tag purification approach (He et al., 2010; Jäger et al., 2012b). We cotransfected HEK293T cells with 2xStrep-tagged Vif proteins and 3xFlag-tagged CUL5 then performed 2-step tandem affinity purification, initially purifying Vif then CUL5 (Figure 3A). Eluates were then subjected to LC-MS/MS analysis. In each sample, we identified high peptide coverage of the Vif and CUL5 baits as well as of proteins associated with the CRL5 complex (ELOB, ELOC, RBX2, and NEDD8) (Figure 3B, C). Consistent with our previous data, peptides from CBFβ were only observed in the SIVmac and HIV-1 Vif samples. Although we failed to identify likely cofactors in the FIV Vif sample, we did observe a highly abundant non-CRL5 complex host factor in the MVV sample: the peptidyl-prolyl isomerase CYPA (Fischer et al., 1984, 1989; Takahashi et al., 1989) (Figure 3B, C). CYPA has been reported previously to interact HIV-1 Capsid (Luban et al., 1993; Thali et al., 1994).
but has never before been implicated to play a direct role in Vif biology. Re-examining our Vif single purification AP-MS dataset (Table S2), we observed that CYPA has a specific and highly scoring interaction with only MVV Vif in both HEK293T cells and Jurkat T-cells (Figure 3D, E). To verify that the CYPA-MVV Vif interaction is not an artifact of expression in human cells, we performed an affinity purification of MVV Vif in natural host sheep (ovine) FLK cells and observed strong association with endogenous ovine CYPA (Figure 3F).

Identification of MVV Vif Residues P21, P24 as Likely CYPA Binding Site

After identifying CYPA as a likely member of the MVV Vif-hijacked CRL5 complex, we performed a limited alanine scan of MVV Vif focusing on proline residues, the substrate of CYPA peptidyl-prolyl isomerase activity. We co-expressed Strep-tagged MVV Vif constructs with 3xFlag-tagged CYPA in HEK293T cells and performed a Flag immunoprecipitation, assaying mutants for co-purification of CYPA (Figure 4A). We identified two MVV Vif mutants that were deficient in CYPA binding: P21A/P24A and P192A. In addition, a BC-box mutant (SLQ::AAA) unable to interact with ELOC also was deficient in CYPA binding, suggesting that at least partial assembly of the Vif-hijacked ubiquitin ligase complex is required for stable interaction between MVV Vif and CYPA. We focused on the P21/P24 region as the site of CYPA binding as the sequence is unique within sheep (MVV) and the closely related goat (CAEV) infecting lentivirus Vif proteins (Figure 4B), while the P192 residue is potentially conserved across the broader genus (Figure S1). Indeed, we observe that CAEV Vif is able to co-purify CYPA in an analogous manner to MVV (Figure S4A), confirming suspicion that the MVV/CAEV clade-specific P21/P24 region is important for CYPA binding.

MVV Vif\textsubscript{21}PxxP\textsubscript{24} Region Binds CYPA Active Site

To determine if the P21/P24 region of MVV Vif is directly responsible for binding CYPA, we performed NMR shift experiments on CYPA in the presence of a Vif peptide. Two-dimensional $^{15}$N-$^1$H chemical shift correlation spectroscopy was performed on labeled CYPA in the unbound state and in the presence of increasing concentrations of a MVV Vif peptide containing both P21 and P24 (MVV Vif\textsuperscript{17–26}). The addition of the Vif peptide (up to 300 μM) induced significant chemical shift perturbations on the protein spectrum, although saturation was not reached even at the highest Vif concentration and a binding constant could not be determined (Figure 4D). Mapping of the resonances that disappeared upon addition of the MVV Vif peptide indicated that the peptide binds to the active site of CYPA (Figure 4C, D). Additional residues surrounding the active site were observed to enter slow exchange mode, or displayed peak broadening (Figure S3C).

To independently verify that MVV Vif interacts with CYPA via the active site of the enzyme, we treated cells expressing 2xStrep-tagged MVV Vif with the CYPA inhibitor cyclosporine A (CsA), which binds to the active site of CYPA and competes for substrate binding (Figure 4C; Takahashi et al., 1989; Thériault et al., 1993). Performing a titration of CsA treatment followed by affinity purification of MVV Vif, we observed a loss of MVV Vif binding to CYPA in the 5 – 10 μM range, with corresponding weakening of ELOC binding (Figure 4E). The CsA concentration required to disrupt CYPA interaction with
MVV Vif is about an order of magnitude greater than our observed concentration required for disrupting the interaction between CYPα and HIV-1 Capsid (Figure S4B). While HIV-1 Capsid binds to CYPα, we find that MVV Capsid does not (Figure S4C). From these experiments, we conclude that MVV Vif binds directly to the CYPα binding site via the PxxP motif.

**CYPα is Critical for MVV Vif-CRL5 Reconstitution**

After observing the CYPα-MVV Vif interaction in vivo, we revisited reconstitution of the MVV Vif-CRL5 complex with the addition of CYPα, in a manner analogous HIV-1 Vif and CBFβ (Jäger et al., 2012b). CYPα rescued MVV Vif-ELOB-LOC complex stability (Figure 4F, G), and allowed for the formation of a stable complex with CUL5-RBX, capable of ubiquitylating ovine A3Z3, but not human A3H, in vitro (Figure 4H).

To determine if MVV Vif-CYPα-CRL5 complex conforms to a similar macromolecular organization as the HIV-1 Vif-CBFβ-CRL5 complex, small angle X-ray scattering (SAXS) analysis was performed on the reconstituted MVV Vif-CYPα-CRL5 complex as well as HIV-1 Vif1-174-CBFβ-CRL5. Both complexes were monodisperse and well-folded under the SAXS experimental conditions, therefore suitable for envelope generation (Figure S5A–C). The pairwise distribution function revealed that both HIV-1 and MVV complexes have similar maximal dimensions (Dmax), with values of 190Å and 200Å, respectively (Figure 4I, Table S3). Analysis of the resulting envelopes revealed that despite different complex constituents the overall surface of the macromolecular assemblies is quite similar with an overall elongated E3 ring-ligase conformation. To determine how well the SAXS envelopes fit the available structure data, a model of HIV-1 Vif-CRL5 was generated. While the HIV-1 Vif-CRL5 model was relatively well fit into its experimental SAXS envelope, with a chi value of 1.89 (Figure S5D), there was a slightly poorer fit into the experimentally determined MVV Vif-CRL5 envelope, possibly due to differences in substrate receptor structure (Figure 4J). This likely reflects different fold of CYPα and CBFβ, and possibly of MVV and HIV-1 Vif proteins.

**Correlated Deficiencies in CYPα Binding and A3 Antagonism in MVV Vif Mutants**

We next asked if CYPα also affected MVV Vif A3 degradation activity. Focusing our analysis on the P21, P24 putative CYPα binding site, we co-expressed 3xHA-tagged ovine A3Z2Z3 (OaA3Z2Z3) with 2xStrep-tagged wild-type, P21A, P24A, P21A/P24A, and SLQ::AAA MVV Vif mutants and observed that the loss of CYPα binding to these mutants correlated with reduction in OaA3Z2Z3 degradation activity (Figure 5A). To determine whether the loss of function MVV Vif mutants were deficient in forming active CRL complexes or merely unable to bind substrate due to structurally compromising mutations, we performed co-affinity purification experiments with Strep-tagged MVV Vif mutants in the presence of HA-tagged OaA3Z2Z3. We observed that both mutants deficient in A3 degradation activity (P21A/P24A and SLQ::AAA) bound OaA3Z2Z3 (Figure 5B), indicating that the mutations prevent proper assembly of a functional CRL complex without disrupting substrate binding.
To test the importance of the MVV Vif-CYPA interaction for viral infectivity in vivo, we performed a spreading infection with MVV strain KV1772 in primary sheep macrophages with wild-type, P21A, P24A, P21A/P24A, or vif-null strains. While all mutants showed reproducibly diminished spreading kinetics compared to wild-type virus, the P21A/P24A mutant showed a greater spreading defect than the individual P21A and P24A mutations, copying the severe spreading defect observed with the SLQ::AAA and vif-null viruses (Figure 5C). The assay was also performed in primary sheep choroid plexus (SCP) cells with similar results (Figure S6E). After spread, we cloned and sequenced the integrated proviruses in each infection to determine if viral restriction correlated with G-to-A mutational load indicative of A3 anti-viral activity. We observed significant increases in G-to-A mutations in P21A/P24A (p = 1.41×10−4), SLQ::AAA (p = 5.27×10−5), and Δvif (p = 1.84×10−5) MVV compared to wild-type using a one-sided Wilcoxon Rank-sum test (SCP cell results, Figure 5D). No significant increase in mutations was observed for either the P21A or the P24A single mutations relative to wild-type (Figure 5D; S7A–C). The trinucleotide sequence preferences of the G-to-A mutations were similar across all conditions (G(G/A)A), again strongly indicative of A3-mediated mutation (Figure 5E, S7D).

**CYPA is Required for Ovine A3 Degradation by MVV Vif**

We tested MVV Vif dependence on CYPA for A3 degradation activity using a CYPA knockdown in human cells, but were unable achieve a knockdown sufficient to prevent either OaA3 degradation or MVV Vif-CRL complex formation using polyclonal lines (data not shown). Titration experiments using CsA showed limited but reproducible inhibition of OaA3/Z2Z3 degradation by MVV Vif, increasing with CsA concentration until about 5 μM when toxicity became apparent (Figure S4B). Importantly, the inhibition was not observed with HIV-1 Vif and its cognate substrate, human A3G (HsA3G) (Figure S4C).

Due to lack of efficacy of either CYPA knockdowns or CsA treatments individually, we attempted to inhibit MVV Vif by combining both protocols, treating a monoclonal CYPA knockdown line with 2 μM CsA and comparing MVV Vif A3 degradation activity to a non-targeting control line. We observed a modest inhibition of Vif-mediated OaA3/Z2Z3 degradation in the knockdown line compared to the control line without CsA treatment. In contrast, we observe near complete inhibition of MVV Vif degradation activity in CYPA-knockdown cells treated with CsA (Figure 6A, Lanes 9 and 10). HIV-1 Vif A3 degradation activity was not affected by CsA treatment in either the knockdown or the control line (Figure S4D), indicating the combination of CYPA knockdown and CsA treatment was specifically and cooperatively interfering with the MVV Vif-CYPA interaction.

As drug and shRNA treatments can have off-target effects, we next performed ovine A3 degradation assays in an isogenic system using a Jurkat T-cell line and CYPA−/− knockout (KO) line (Braaten and Luban, 2001). ImmunobLOTS confirmed the lack of CYPA expression in the Jurkat CYPA−/− KO line compared to the parental Jurkat E6-1 CYPA+/+ line (Figure 6B). The KO line or the parental line was then nucleofected with an HA-tagged OaA3/Z2Z3 expression construct in the presence or absence of Strep-tagged MVV Vif and Flag-tagged CYPA complementation (Figure 6B). We observe a complete loss of MVV Vif-mediated degradation of OaA3/Z2Z3 in the CYPA−/− KO line (Figure 6C top, lanes 5 & 6) which can
be rescued upon complementation with exogenous CYPA (Figure 6C top, lanes 7 & 8). We were unable to detect expression of MVV Vif in the CYPA−/− KO line without exogenous CYPA complementation, suggesting MVV Vif stability depends on CYPA presence in vivo. This closely mimics the stability requirements of HIV-1 Vif on CBFβ and is consistent with our in vitro reconstitution results with MVV Vif. We did not observe any dependence on exogenous CYPA expression for MVV Vif A3 degradation activity in the parental Jurkat E6-1 CYPA+/+ line (Figure 6C, bottom), and did not observe any dependence on CYPA for A3 degradation activity for HIV-1 Vif and HsA3G in either cell line (Figure 6D).

Lastly, we assessed whether or not various active-site mutants of CYPA could also rescue MVV function in the knockout background. We tested three CYPA mutants – R55K, F113W, and H126A – all located within the active site of CYPA and previously reported to affect activity (Figure S7A; Bosco et al., 2010). We found that two mutants, R55K and F113W, failed to rescue MVV Vif A3 degradation activity in the CYPA−/− KO line, and that a third mutant, H126A, was able to rescue activity as efficiently as wild-type CYPA (Figure 6E). Similar results were obtained in the monoclonal CYPA knockdown line (Figure S7B). We additionally tested the CYPA mutants for MVV Vif binding through in vitro reconstitution, and found that all three were capable of forming a stable MVV Vif-ELOB-ELOC-CYPA complex (Figures S7C, D). While it is possible that the lack of R55K and F113W rescue of MVV Vif activity is due to a weakening of binding in vivo, the in vitro binding data suggests CYPA isomerase activity is important for MVV Vif A3 degradation activity.

DISCUSSION

The retrovirus family infects a diverse set of mammalian hosts, with each viral lineage required to evolve a mechanism to overcome the host challenge to infection presented by A3 proteins. Solutions to this APOBEC3 host challenge by retroviruses include the lentivirus protein Vif that induces the proteasomal degradation of A3 proteins (LaRue et al., 2010; Sheehy et al., 2002; Yu et al., 2003), sequestration of A3 proteins away from virions by the foamy virus protein Bet (Löchelt et al., 2005), or preventing A3 binding to virion proteins in HTLV-1 (Derse et al., 2007). Even within lentiviruses, the equine infectious anemia virus has evolved a Vif-independent, non-degrading mechanism of escaping A3 restriction (Bogerd et al., 2008). Through a series of proteomic, virological, biochemical and structural approaches targeting five evolutionarily distinct lentiviral Vif proteins from HIV-1, SIVmac, MVV, BIV and FIV, we present data consistent with a model of high biochemical plasticity at the molecular level but “modular conservation” due to their conserved function of ubiquitylation and subsequent proteasomal degradation of host A3 restriction factors (Figure 7).

Using AP-MS, we identified a conserved core ubiquitin ligase complex – CUL5-ELOB-ELOC-RBX2 – involved in Vif-mediated degradation of host A3 proteins. For a functional complex, HIV and SIVmac Vif proteins additionally require the host cofactor CBFβ for both complex assembly and activity (Han et al., 2014; Hultquist et al., 2012; Zhang et al., 2012). Our data both identify the CBFβ interaction with HIV-1 and SIVmac Vif proteins and demonstrate their dependence on this cofactor for A3 degradation activity. The interaction
with CBFβ was not observed by AP-MS nor was it functionally required for A3 degradation activity in the non-primate lentiviral Vif proteins, consistent with recent observations (Ai et al., 2014; Han et al., 2014; Zhang et al., 2014a, 2014b). We identified one non-primate lentivirus, BIV, with a Vif protein that requires no non-canonical host cofactor for both complex assembly and activity in vitro, and identified another, MVV, with a Vif protein that requires a novel non-canonical host cofactor, CYPA, to play a CBFβ-like role in regulating ligase assembly and activity both in vitro and in vivo. Though no FIV Vif cofactor was identified, we cannot exclude the possibility that it requires an as of yet unidentified one.

Interaction of MVV Vif with Non-Canonical Cofactor CYPA

The interaction between MVV Vif and CYPA appears to be unique among the lentiviruses examined in this study. Through a combination of targeted mutagenesis and NMR spectroscopy, we identified a di-proline motif in the N-terminus of MVV Vif, 20GPQLP24, which directly binds the CYPA active site. This site is uniquely found in MVV and the closely related CAEV Vif proteins (Figure 4B). The motif bears some resemblance to the CYPA binding site of HIV-1 Capsid, 89GPIAP93 (Gamble et al., 1996), a GPxxP motif. However, the strength of the interaction between MVV Vif and CYPA appears to be much greater than that of CYPA and HIV-1 Capsid as assessed by interaction disruption by CsA treatment (Figure 4E, S5A). Further to this point, the relatively low affinity measured by NMR spectroscopy between CYPA and MVV Vif17–28 peptide is incompatible with the observed stability of the reconstituted MVV Vif-ELOB-ELOC-CYPA complex. These data suggest binding surfaces on MVV Vif in addition to the identified di-proline motif, and are likely outside of the active site of CYPA as evidenced by the inefficacy of CsA treatment in disrupting MVV Vif-CYPA interaction or inhibiting MVV Vif anti-A3 activity without complementary knockdown of CYPA (Figure 6A).

Cellular chaperones interact with a large contingent of clients to catalyze their folding, and often interact with their substrates via general features, such as hydrophobic patches, rather than specific protein-protein interaction surfaces or domains (Jaya et al., 2009; Spiess et al., 2006). The relatively promiscuous interactions of CYPA combined with a high cellular concentration may have eased the evolution of MVV Vif to capture CYPA. If the interaction between the two proteins is mechanistically unrelated to perturbing endogenous CYPA activities, this may explain the selection of CYPA by the virus. The capture of CYPA by MVV Vif would involve transition of the CYPA interaction from a potentially catalytic one in aiding Vif folding to a stoichiometric one in forming a stable complex. The importance of CYPA catalytic function for MVV Vif appears to be retained, as two CYPA active-site mutants appear to bind MVV Vif without forming an active A3 degrading complex (Figure 6E). The one CYPA mutant which was not deficient in this activity, H126A, had been previously shown to be active with an HIV-1 Capsid substrate (Bosco et al., 2010). This model of capture would likely not apply to the interaction between primate lentiviral Vif proteins and CBFβ, as the interaction falls in a specific protein-protein interaction surface evolved by CBFβ to interact with the runt domain of RUNX transcription factors (Guo et al., 2014).
**Cofactor Acquisition as Gain-of-Function Adaptations**

While we cannot definitively infer the ancestral form of Vif-hijacked CRL complex, parsimony suggests the ancestral form would resemble the BIV Vif-hijacked complex. BIV Vif most resembles an endogenous BC-box E3 substrate adaptor, which bind CRL2/5 complexes without the need of non-canonical cofactors. The parsimony model would imply that the interactions between Vif and non-canonical host cofactors (MVV – CYPA; HIV-1/ SIVmac – CBFβ) are derived interactions that occurred independently during the evolution of modern lentiviruses. Why these interactions evolved or what selective advantage they may grant to the viruses remains unclear. We previously suggested that the interaction between HIV-1 Vif and CBFβ may disrupt the endogenous activities of RUNX transcription factors (Jäger et al., 2012b), and have shown Vif-mediated interference of RUNX controlled genes in T-lymphocytes (Kim et al., 2013). This “dual-hijacking” may also exist for the MVV – CYPA interaction, although it is worth noting that CYPA is a highly abundant protein in virtually every cell type, and therefore the secondary effect would necessarily be one that required relatively small changes in cellular CYPA abundance, or involve local effects proximate to MVV Vif activity.

Another driving force in the evolution of novel Vif cofactors is the evolution of the viral proteins’ substrates, the A3 family. The number of A3 genes in a given mammalian genome varies widely, from only a single gene in mice to seven members in primates (Bogerd et al., 2008; Jarmuz et al., 2002; LaRue et al., 2008; Münk et al., 2008). The acquisition of CBFβ as a Vif cofactor by primate lentiviruses coincides with the expansion of A3 family of proteins in primates, and it is possible that the cofactor acquisition enabled Vif to preserve viral fitness without the need to evolve another, non-CRL mechanism to recognize and degrade the larger A3 substrate repertoire (Ai et al., 2014). A recent structure of the SIV/ HIV-2 accessory factor Vpx showed the co-crystallized Cullin-4A adapter protein DCAF1 directly contacts the viral substrate SAMHD1 (Schwefel et al., 2014); this example may be generalizable to a model of host factors extending the viral E3 surface for substrate recognition. The A3 expansion driving cofactor acquisition model would fail to explain the interaction between MVV Vif and CYPA, as the ovine genome shows no increase in the number of A3 proteins compared with the bovine genome, and one less than the feline genome (LaRue et al., 2008; Münk et al., 2008). Interestingly, MVV Vif is observed to have a high promiscuity for A3 proteins, showing activity against many non-cognate A3’s (LaRue et al., 2010), potentially supporting model of cofactor-mediated substrate expansion.

An intriguing possibility is that non-canonical cofactors act to increase the evolvability of their Vif partner, enabling Vif proteins to retain activity with otherwise lethal mutations during transitions to more fit states. Restriction factors are a major barrier to zoonosis (Sharp and Hahn, 2011), and a Vif protein able to adapt more quickly to a new host’s A3 proteins should grant the lentivirus a competitive advantage in zoonotic transmission, as well as in populations with diverse restriction factor haplotypes (Binka et al., 2012; Ooms et al., 2013). Whether gaining an interaction partner makes a viral protein more robust to mutation is debatable, as the benefits of stabilization via the interaction may be outweighed by the mutational constrains imposed by the interaction itself. HIV-1 Vif must maintain direct interactions with ELOC, CUL5, multiple A3 proteins, and a large surface with CBFβ to be
functional, yet even after the establishment of the interaction between CBFβ and primate lentivirus Vif, it has recently undergone dramatic sequence changes (Etienne et al., 2013).

**CYPA Potentially Bridges Vif Antagonism of A3 With TRIM5α Escape**

We explored the idea of whether or not the interaction between CYPA and MVV Vif may be related to the genetic conflict between lentiviruses and the host restriction factor TRIM5α (Stremlau et al., 2004). In HIV-1, CYPA interaction with the viral capsid is involved in mitigating the anti-viral actions of TRIM5α (Sokolskaja and Luban, 2006), and some old world primate hosts have evolved a TRIM5α–CYPA fusion protein, TRIMCYP, which uses its CYPA-domain to recruit the TRIM5α domain to the viral core (Nisole et al., 2004; Sayah et al., 2004). MVV is restricted by sheep TRIM5α when overexpressed in cell culture, but the mechanism by which MVV avoids this restriction in vivo is unknown (Jáuregui et al., 2012). It remains possible that the interaction between CYPA and MVV Vif is to allow crosstalk of Vif between two different host restriction pathways – A3 and TRIM5α, particularly if there exists an as of yet unidentified TRIMCYP gene in the sheep genome.

In addition to its role in TRIM5α-mediated restriction, the interaction of CYPA with HIV-1 Capsid has recently been found to be essential for the virus to evade detection by the innate immune sensor cGAS and to avoid subsequent activation of the innate immune response (Lahaye et al., 2013; Rasaiyaah et al., 2013). Intriguingly, a pair of mutants in MVV Vif and Capsid (P205S and L120R, respectively) results in a restricted growth phenotype, while neither mutant alone impacts replication (Gudmundsson et al., 2005). Whether or not this is related to the MVV Vif interaction with CYPA is under investigation.

**Modular Conservation and Lineage-Specific Interactions**

We have shown that despite a generally conserved mechanism of mediating host A3 degradation by ubiquitylation and subsequent proteasomal degradation, lentiviruses demonstrate surprising plasticity in the biochemical requirements for this activity through their Vif proteins. While other lentiviruses have been observed to change viral protein-host substrate interactions (Lim et al., 2012; Sauter et al., 2009) or the sites of substrate recognition (Fregoso et al., 2013), Vif is unique in that the viral protein substrate and the core machinery required for activity appear to be conserved and yet cofactor interaction partners are varied and lineage-specific. We have previously noted this concept of “modular conservation” where the function of biochemical modules is conserved but the underlying molecular interactions between the modules have changed significantly. For example, we have shown that although genetic interactions between different species have evolved rapidly, the genetic relationships within protein complexes, or modules, are highly conserved (Beltrao et al., 2010; Roguev et al., 2008; Ryan et al., 2012). In this vein, it remains to be seen whether or not the Vif paradigm is generalizable, but it is clear that viral proteins, even in the context of “stable” interactions with host factors, can still undergo rapid and surprisingly dramatic changes over the course of virus evolution.
EXPERIMENTAL PROCEDURES

Detailed experimental procedures are available in the Supplemental Experimental Procedures.

Expression Constructs

HIV-LAI, SIVmac239, BIV, FIV, and MVV Vif constructs in pVR1012 (Vical Co.) have been reported previously (LaRue et al., 2010).

Ovine cells and MVV infections

SCP cells and sheep blood-derived macrophages were infected with RT-normalized wild-type and mutant viruses for spreading infection assays. Samples were taken daily for Taqman qPCR.

Affinity Purifications

Affinity purifications (AP) were generally performed as described previously (Jäger et al., 2012a).

Mass Spectrometry Data and Analysis

Digested peptide mixtures were analyzed on either a Thermo Scientific Velos Pro or a Thermo Scientific LTQ XL ion trap mass spectrometry system. Data were searched against a database containing SwissProt Human protein sequences. Interactions were scored using the SAINT algorithm (Choi et al., 2011) with prey identified spectral counts.

In vitro Reconstitution and Ubiquitylation Assays

Vif complexes for in vitro work were produced by coexpression in BL21-Star(DE3)pLysS cells. CUL5-RBX2, and all ubiquitin and Nedd8 pathway components used in ubiquitylation assays were obtained as previously described (Stanley et al., 2012).

CYPA Knockdown and Cyclosporine Treatment

CYPA knockdown lines were generated in HEK293T cells using pLKO.1 derived lentiviruses encoding an shRNA targeting CYPA (TRCN0000049277). For assays involving cyclosporine A (CsA) (#9973, CST), cells were treated with 2–5 μM CsA 4–6 hours post-transfection to prevent potential loss in transfection efficiency.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors wish to thank members of the Krogan, Gross, Fraser, Harris, and Andrésdóttir labs; P. Hartley for assisting in stable line generation; R. LaRue for cloning of MVV, BIV, FIV, and SIVmac Vif plasmids; S. Jäger, S. Chen, M. Eckhardt, and D. Gordon for reagents; Z. Rizvi for CYPA cloning; S.J., C. Mahon, and G. Jang for expertise and advice in affinity purifications; E. Verschueren and P. Cimermančič for advice on AP-MS scoring; M. Shales for assistance in figure construction; we would kindly thank S. J. Kim for help in collecting SAXS profiles, and D. Schneidman for her assistance in generating the HIV E3 model and analyzing the SAXS data using the

Cell Rep. Author manuscript; available in PMC 2016 May 26.
AllosMod-FoXS server; we are indebted to H. I. Gunnarsson and A. Adalbjornsdottir for expert technical help. The following reagents were obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Jurkat Clone E6-1 from Dr. A. Weiss and Jurkat T-Cells CypA −/− from Drs. D. Braaten and J. Luban. J.R.K. was supported by an NSF graduate research fellowship. This work was supported by NIH grants to N.J.K (P50 GM082250, P50 GM081879, and P01 AI090935) and to R.S.H. (R01 AI064046 and P01 GM091743), and a grant from the Icelandic Research Fund to V.A. (141085-051).

References

Ai Y, Zhu D, Wang C, Su C, Ma J, Ma J, Wang X. Core-binding factor subunit beta is not required for non-primate lentiviral Vif mediated APOBEC3 degradation. J Virol. 2014

Beltrao P, Cagney G, Krogan NJ. Quantitative genetic interactions reveal biological modularity. Cell. 2010; 141:739–745. [PubMed: 20510918]

Binka M, Ooms M, Steward M, Simon V, Manuscript R, Health TG, Gustave O, Place LL. The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H. J Virol. 2012; 86:49–59. [PubMed: 22013041]

Bogerd HP, Tallmadge RL, Oaks JL, Carpenter S, Cullen BR. Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism. J Virol. 2008; 82:11889–11901. [PubMed: 18818324]

Bosco, Da; Eisenmesser, EZ.; Clarkson, MW.; Wolf-Watz, M.; Labeikovsky, W.; Millet, O.; Kern, D. Dissecting the microscopic steps of the cyclophilin A enzymatic cycle on the biological HIV-1 capsid substrate by NMR. J Mol Biol. 2010; 403:723–738. [PubMed: 20708627]

Braaten D, Luban J. Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells. EMBO J. 2001; 20:1300–1309. [PubMed: 11250896]

Choi H, Larsen B, Lin ZY, Breitkreutz A, Mellacheruvu D, Fermin D, Qin ZS, Tyers M, Gingras AC, Nesvizhskii AI. SAINT: probabilistic scoring of affinity purification-mass spectrometry data. Nat Methods. 2011; 8:70–73. [PubMed: 21131968]

Davis ZH, Verschueren E, Jang GM, Kleffman K, Johnson JR, Park J, Von Dollen J, Maher MC, Johnson T, Newton W, et al. Global Mapping of Herpesvirus-Host Protein Complexes Reveals a Transcription Strategy for Late Genes. Mol Cell. 2015; 57:349–360. [PubMed: 25544563]

Derse D, Hill Sa, Prineler G, Lloyd P, Heidecker G. Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid. Proc Natl Acad Sci U S A. 2007; 104:2915–2920. [PubMed: 17299050]

Etienne L, Hahn BH, Sharp PM, Matsen Fa, Emerman M. Gene loss and adaptation to hominids underlie the ancient origin of HIV-1. Cell Host Microbe. 2013; 14:85–92. [PubMed: 23870316]

Fischer G, Bang H, Mech C. Determination of enzymatic catalysis for the cis-trans-isomerization of peptide binding in proline-containing peptides. Biomed Biochim Acta. 1984; 43:1101–1111. [PubMed: 6395866]

Fischer G, Wittmann-Liebold B, Lang K, Kiehhaber T, Schmid FX. Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature. 1989; 337:476–478. [PubMed: 2492638]

Fregoso OI, Ahn J, Wang C, Mehrens J, Skowronski J, Emerman M. Gene loss and adaptation to hominids underlie the ancient origin of HIV-1. Cell Host Microbe. 2013; 14:85–92. [PubMed: 23870316]

Fischer G, Bang H, Mech C. Determination of enzymatic catalysis for the cis-trans-isomerization of peptide binding in proline-containing peptides. Biomed Biochim Acta. 1984; 43:1101–1111. [PubMed: 6395866]

Fregoso OI, Ahn J, Wang C, Mehrens J, Skowronski J, Emerman M. Gene loss and adaptation to hominids underlie the ancient origin of HIV-1. Cell Host Microbe. 2013; 14:85–92. [PubMed: 23870316]

Fischer G, Bang H, Mech C. Determination of enzymatic catalysis for the cis-trans-isomerization of peptide binding in proline-containing peptides. Biomed Biochim Acta. 1984; 43:1101–1111. [PubMed: 6395866]

Fischer G, Wittmann-Liebold B, Lang K, Kiehhaber T, Schmid FX. Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature. 1989; 337:476–478. [PubMed: 2492638]

Fregoso OI, Ahn J, Wang C, Mehrens J, Skowronski J, Emerman M. Evolutionary toggling of Vpx/Vpr specificity results in divergent recognition of the restriction factor SAMHD1. PLoS Pathog. 2013; 9:e1003496. [PubMed: 23874202]

Gamble TR, Vajdos FF, Yoo S, Worthylake DK, Houseweart M, Sundquist W, Hill CP. Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell. 1996; 87:1285–1294. [PubMed: 8980234]

Greninger AL, Knudsen GM, Betegon M, Burlingame AL, Derisi JL. The 3A protein from multiple picornaviruses utilizes the golgi adaptor protein ACBD3 to recruit PH4KIII+. J Virol. 2012; 86:3605–3616. [PubMed: 22258260]

Gudmundsson B, Jónsson SR, Olafsson O, Aagnarðsdóttir G, Matthíasdóttir S, Georgsson G, Torsteinsdóttir S, Svansson V, Kristbjörnsdóttir HB, Franzdóttir SR, et al. Simultaneous mutations in CA and Vif of Maedi-Visna virus cause attenuated replication in macrophages and reduced infectivity in vivo. J Virol. 2005; 79:15038–15042. [PubMed: 16306574]

Cell Rep. Author manuscript; available in PMC 2016 May 26.
by the Innate Sensor cGAS in Dendritic Cells. Immunity. 2013; 39:1132–1142. [PubMed: 24269171]

LaRue RS, Jónsson SR, Silverstein KAT, Lajoie M, Bertrand D, El-Mabrouk N, Hötzl I, Andrésdóttir V, Smith TPL, Harris RS. The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals. BMC Mol Biol. 2008; 9:104. [PubMed: 19017997]

LaRue RS, Lengel J, Jónsson SR, Andrésdóttir V, Harris RS. Lentiviral Vif degrades the APOBEC3Z3/APOBEC3H protein of its mammalian host and is capable of cross-species activity. J Virol. 2010; 84:8193–8201. [PubMed: 20519393]

Lim ES, Fregoso OI, McCoy CO, Matsen FA, Malik HS, Emerman M. The ability of primate lentiviruses to degrade the monocyte restriction factor SAMHD1 preceded the birth of the viral accessory protein Vpx. Cell Host Microbe. 2012; 11:194–204. [PubMed: 22284954]

Löchelt M, Romen F, Bastone P, Muckenfuss H, Kirchner N, Kim YB, Truyen U, Rösler U, Battenberg M, Saib A, et al. The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein. Proc Natl Acad Sci U S A. 2005; 102:7982–7987. [PubMed: 15911774]

Luban J, Bossolt KL, Franke EK, Kalpana GV, Goff SP. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell. 1993; 73:1067–1078. [PubMed: 8513493]

Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature. 2003; 424:99–103. [PubMed: 12808466]

Miyagi E, Kao S, Yedavalli V, Strebel K. CBFβ enhances de novo protein biosynthesis of its binding partners HIV-1 Vif and RUNX1 and potentiates the Vif-induced degradation of APOBEC3G. J Virol. 2014; 88:4839–4852. [PubMed: 24522927]

Münk C, Beck T, Zielonka J, Hotz-Wagenblatt A, Chareza S, Battenberg M, Thielebein J, Cichutek K, Bravo IG, O’Brien SJ, et al. Functions, structure, and read-through alternative splicing of feline APOBEC3 genes. Genome Biol. 2008; 9:R48. [PubMed: 18315870]

Nisole S, Lynch C, Stoye JP, Yap MW. A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1. Proc Natl Acad Sci U S A. 2004; 101:13324–13328. [PubMed: 15326303]

Ooms M, Brayton B, Letko M, Maio SM, Pilcher CD, Hecht FM, Barbour JD, Simon V. HIV-1 Vif Adaptation to Human APOBEC3H Haplotypes. Cell Host Microbe. 2013; 14:411–421. [PubMed: 24139399]

Ramage HR, Kumar GR, Verschueren E, Johnson JR, Von Dollen J, Johnson T, Newton B, Shah P, Horner J, Krogan NJ, et al. A Combined Proteomics/Genomics Approach Links Hepatitis C Virus Infection with Nonsense-Mediated mRNA Decay. Mol Cell. 2015; 57:329–340. [PubMed: 25616068]

Rasaiyaah J, Tan CP, Fletcher AJ, Price AJ, Blondeau C, Hilditch L, Jacques Da, Selwood DL, James LC, Noursadeghi M, et al. HIV-1 evades innate immune recognition through specific cofactor recruitment. Nature. 2013; 503:402–405. [PubMed: 24196705]

Roguev A, Bandypopadiyay S, Zofall M, Zhang K, Fischer T, Collins SR, Qu H, Shales M, Park H, Hayles J, et al. Conservation and rewiring of functional modules revealed by an epistasis map in fission yeast. Science. 2008; 322:405–410. [PubMed: 18818364]

Ryan CJ, Roguev A, Patrick K, Xu J, Jahari H, Tong Z, Beltrao P, Shales M, Qu H, Collins SR, et al. Hierarchical modularity and the evolution of genetic interactomes across species. Mol Cell. 2012; 46:691–704. [PubMed: 22681890]

Sauter D, Schindler M, Specht A, Landford WN, Münch J, Kim KA, Votelle J, Schubert U, Bibollet-Ruche F, Keele BF, et al. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe. 2009; 6:409–421. [PubMed: 19917496]

Sayah DM, Sokolskaja E, Berthoux L, Luban J. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature. 2004; 430:569–573. [PubMed: 15243629]
Schwefel D, Groom HCT, Boucherit VC, Christodoulou E, Walker PA, Stoye JP, Bishop KN, Taylor IA. Structural basis of lentiviral subversion of a cellular protein degradation pathway. Nature. 2014; 505:234–238. [PubMed: 24336198]

Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med. 2011; 1:a006841. [PubMed: 2229120]

Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 2002; 418:646–650. [PubMed: 12167863]

Sheehy AM, Gaddis NC, Malim MH. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med. 2003; 9:1404–1407. [PubMed: 14528300]

Sokolskaja E, Luban J. Cyclophilin, TRIM5, and innate immunity to HIV-1. Curr Opin Microbiol. 2006; 9:404–408. [PubMed: 16815734]

Spiess C, Miller EJ, McClellan AJ, Frydman J. Identification of the TRiC/CCT substrate binding sites uncovers the function of subunit diversity in eukaryotic chaperonins. Mol Cell. 2006; 24:25–37. [PubMed: 17018290]

Stanley DJ, Bartholomeeusen K, Crosby DC, Kim DY, Kwon E, Yen L, Cartozo NC, Li M, Jäger S, Mason-Herr J, et al. Inhibition of a NEDD8 Cascade Restores Restriction of HIV by APOBEC3G. PLoS Pathog. 2012; 8:e1003085. [PubMed: 14985764]

Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature. 2004; 427:848–853. [PubMed: 14985764]

Tahirov TH, Inoue-Bungo T, Morii H, Fujikawa A, Sasaki M, Kimura K, Shiina M, Sato K, Kumasaka T, Yamamoto M, et al. Structural analyses of DNA recognition by the AML1/Runx-1 Run domain and its allosteric control by CBFBeta. Cell. 2001; 104:755–767. [PubMed: 11257229]

Takahashi N, Hayano T, Suzuki M. Peptidyl-prolyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin. Nature. 1989; 337:473–475. [PubMed: 2644542]

Tan MJA, White EA, Sowa ME, Harper JW, Aster JC, Howley PM. Cutaneous β-human papillomavirus E6 proteins bind Mastermind-like coactivators and repress Notch signaling. Proc Natl Acad Sci U S A. 2012; 109:E1473–E1480. [PubMed: 22547818]

Thali M, Bukovsky A, Kondo E, Rosenwirth B, Walsh CT, Sodroski J, Göttlinger HG. Functional association of cyclophilin A with HIV-1 virions. Nature. 1994; 372:363–365. [PubMed: 7969495]

Thériault Y, Logan TM, Meadows R, Yu L, Olejniczak ET, Holzman TF, Simmer RL, Fesik SW. Solution structure of the cyclosporin A/cyclophilin complex by NMR. Nature. 1993; 361:88–91. [PubMed: 8421500]

White, EA; Kramer, RE.; Tan, MJA.; Hayes, SD.; Harper, JW.; Howley, PM. Comprehensive analysis of host cellular interactions with human papillomavirus E6 proteins identifies new E6 binding partners and reflects viral diversity. J Virol. 2012a; 86:13174–13186. [PubMed: 23015706]

White EA, Sowa ME, Jie M, Tan A, Jeudy S, Hayes SD, Santha S, Münger K, Harper JW, Howley PM, et al. Systematic identification of interactions between host cell proteins and E7 oncoproteins from diverse human papillomaviruses. Proc Natl Acad Sci U S A. 2012b; 109:E260–E267. [PubMed: 22232672]

York A, Hutchinson EC, Fodor E. Interactome Analysis of the Influenza A Virus Transcription/Replication Machinery Identifies Protein Phosphatase 6 as a Cellular Factor Required for Efficient Virus Replication. J Virol. 2014; 88:13284–13299. [PubMed: 25187537]

Yu XXF, Yu Y, Liu B, Luo K, Kong W, Mao P. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science. 2003; 302:1056–1060. [PubMed: 14564014]

Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature. 2003; 424:94–98. [PubMed: 12808465]

Zhang J, Wu J, Wang W, Wu H, Yu B, Wang J, Lv M, Wang X, Zhang H, Kong W, et al. Role of cullin-elonginB-elonginC E3 complex in bovine immunodeficiency virus and maedi-visna virus Vif-mediated degradation of host A3Z2-Z3 proteins. Retrovirology. 2014a; 11:77. [PubMed: 25213124]
Zhang W, Du J, Evans SL, Yu Y, Yu XF. T-cell differentiation factor CBF-β regulates HIV-1 Vif-mediated evasion of host restriction. Nature. 2012; 481:376–379. [PubMed: 22190036]

Zhang W, Wang H, Li Z, Liu X, Liu G, Harris RS, Yu X-F. Cellular Requirements for BIV Vif-Mediated Inactivation of Bovine APOBEC3 Proteins. J Virol. 2014b
FIGURE 1. Proteomic analysis of lentiviral Vif proteins

(A) Percent identity and percent similarity matrix of Vif proteins used in this study. Distance tree generated from Gagpol protein sequence of viruses, with bootstrap support values.

(B) Flow-chart of affinity purification – mass spectrometry (AP-MS) pipeline used to identify Vif-interacting host proteins.

(C) Representative silver stained SDS-PAGE of eluates from a Vif-Strep purification in transiently transfected HEK293T cells. Asterisks indicate Vif proteins.

(D) Cullin ubiquitin ring ligase (CRL) complex proteins identified in AP-MS experiments, colored by SAINT score and clustered hierarchically by correlation.

(E) Immunoblot of a Strep affinity purification of Strep-tagged Vif proteins transiently expressed in HEK293T cells, probing for CRL proteins highlighted in panel (D).

See also Figures S1, S2; Tables S1, S2.
FIGURE 2. Vif dependence on CBFβ is primate lentivirus-specific

(A) Schema of single-round infection assay.

(B–F) Infectivity assays described in panel (A), using Vif proteins and cognate A3 proteins. Bars represent mean ± S.E. of GFP expression from virus reporter lines. Viral, A3, and CBFβ proteins are detected by immunoblot. VLPs: virus-like particles.

(G) UV absorbance curves are shown for gel filtration of CUL5-RBX2 (C5R2) alone, or mixed with an excess of indicated Vif complexes (HIV VCBC = Vif-ELOB-ELOC-CBFβ, BIV VCB = Vif-ELOB). Peaks are observed at earlier elution volumes when C5R2 is mixed with Vif complexes, indicating E3 complex formation.
(H) Coomassie-blue stained SDS-PAGE of peak fractions collected from gel filtration runs shown in panel (G). Vif bands are indicated by an asterisk, and cofactor CBFβ is indicated by a circle.

(I) Immunoblot of ubiquitylation reactions with either HIV-1 Vif or BIV Vif E3, using myc-tagged C-terminal domain of human A3F (myc-HsA3F CTD) or bovine A3Z3 (myc-BtA3Z3) as substrate, respectively. Ub: ubiquitin; Me-Ub: methylated ubiquitin.
FIGURE 3. CYPA is Tightly and Uniquely Associated with MVV Vif

(A) Cartoon of double affinity purification experiment.

(B) LC-MS/MS mass spectrometry results from the double purification of 2xStrep-tagged Vif proteins and 3xFlag-tagged CUL5. Bars indicate peptide percent coverage of proteins identified in eluates after second purification step.

(C) Immunoblot of input lysates, first and second purification eluates used for MS analysis in panel (B).

(D) Heatmap of AP-MS data for CYPA in HEK293T and Jurkat T-cell lines. Color indicates SAINT score.

(E) Re-probing of immunoblot of Strep affinity purification shown in Figure 1F; ELOC is shown as a control for CRL complex interaction.

(F) Strep purification of MVV Vif from transient transfection of ovine FLK cells. CYPA, ELOC, and Vif are detected by immunoblot.
FIGURE 4. CYP\(A\) is a Component of the MVV Vif-Hijacked CRL Complex

(A) Co-purification testing in vivo interaction between CYP\(A\) and either wild-type or mutant MVV Vif. CYP\(A\)-Flag and various MVV Vif-Strep constructs are co-transfected, followed by a Flag immunoprecipitation. Co-purification of MVV Vif constructs is assayed by immunoblot.

(B) Multiple sequence alignment of MVV, CAEV, and the other Vif proteins used in this study (BIV, FIV, SIVmac, HIV-1) referenced to the first 30 amino acids of MVV Vif. Residues P21 and P24 are highlighted, as well as the region used for CYP\(A\)-binding assay in panel (D). Residues are colored by percent identity.

(C) Two-dimensional \(^{15}\)N-\(^{1}\)H chemical shift mapping of CYP\(A\) in presence of MVV Vif\(^{17–26}\) peptide. The resonances of Y48, R55, I56, I57, F60, M61, C62, Q63, G65, G72, L98, S99, A101, Q111, F112, E120, W121 and K125 (orange sticks) shift, then disappear upon addition of the Vif peptide. CsA is labeled in blue. PDB: 1CWA.

(D) Column 1: Representative example of a CYP\(A\) residue (G135) that is not affected by the presence of the MVV Vif peptide. Column 2: By comparison, R55 and S99 undergo significant chemical shift and intensity reduction. The bars are scaled to the intensity of the HSQC peak at the corresponding Vif concentration.

(E) Affinity purification of MVV Vif in presence of a titration of CsA. Co-purification of endogenous Vif interactors is assayed by immunoblot. BC-box and proline mutants are used as controls for ELOC and CYP\(A\) binding, respectively. E: Ethanol.

(F) UV absorbance curves are shown for gel filtration of CUL5-RBX2 (C5R2) alone, or mixed with an excess of indicated Vif complexes (MVV VCBC = Vif-ELOB- ELOC-
CYPA). Peaks are observed at earlier elution volumes when C5R2 is mixed with Vif complexes, indicating E3 complex formation. (G) Coomassie-blue stained SDS-PAGE of peak fractions collected from gel filtration runs shown in panel (F).

(H) Immunoblot of methyl-ubiquitylation reactions with MVV E3 and either myc-tagged human A3H (myc-HsA3H) or ovine A3-Z3 (myc-OaA3-Z3).

(I) Pair distance distribution function, $P(r)$, calculated from SAXS intensity data.

(J) Molecular envelopes of HIV-1 Vif$^{1-174}$-CBFβ-CRL5 (left) and MVV Vif-CYPA-CRL5 (right) calculated from $P(r)$. An HIV-1 E3 model was superimposed into both envelopes. See also Figures S3, S5; Table S3.
FIGURE 5. MVV Vif Mutants Deficient in CYPα-Binding are Deficient in A3 Antagonism and Cannot Promote MVV Infectivity in situ

(A) Co-transfection of HA-tagged ovine A3Z2Z3 (OaA3Z2Z3-HA) and either wild-type or proline mutant MVV Vif. A3 stability in the presence of Vif is assayed by immunoblot.

(B) Co-affinity purification between OaA3Z2Z3 and MVV Vif constructs that were deficient in OaA3Z2Z3 destabilization in panel (A). Interaction between A3 and Vif proteins is assayed by immunoblotting.

(C) MVV spreading assay in ovine primary macrophage cells. Lysates were harvested at various time points post-infection, and virus genome copies were quantified using TaqMan-based real-time PCR assay, mean ± S.E. (n=3).

(D) Hypermutation assay of MVV strain KV1772. MVV with either wild-type or mutant vif were subjected to a single-cycle infection assay in primary sheep choroid plexus (SCP) cells, and produced viruses were then used to infect cells, pro-viruses cloned, and assayed for A3-mediated G-to-A mutations. Wild-type, P24A: n=20; P21A: n=16; P21A/P24A: n=17; SLQ::AAA: n=19; Δvif: n=10. Significance values were determined by a one-sided Wilcoxon Rank-Sum Test compared to wild-type; no annotated p-value indicates p-value > 0.05.

(E) Tri-nucleotide context of G-to-A mutations measured in panel (C). Other refers to any GNN tri-nucleotide other than GGA or GAA.

See also Figure S6.
FIGURE 6. CYPA is Required for MVV Vif A3 Degradation Activity

(A) Comparison of Vif A3 degradation activity in monoclonal CYPA knockdown versus control cells in the presence or absence of CsA. Cells were transiently transfected with HA-tagged ovine A3Z2Z3 (OaA3-Z2Z3) and either wild-type or BC-box mutant (SLQ::AAA) Strep-tagged MVV Vif, then treated 6 hours later with either ethanol (E) or 2 μM CsA overnight. Bars represent HA immunoreactivity normalized first by GAPDH loading control, then to no Vif control for each cell line; mean ± S.E. (n=3). Proteins are detected by immunoblotting.

(B) CYPA immunoblot in Jurkat E6-1 CYPA+/+ “parental” line and derived E6-1 CYPA−/− knockout (KO) line.

(C) Top: Jurkat CYPA−/− KO cells are transiently transfected with HA-tagged OaA3Z2Z3, Strep-tagged MVV Vif, and Flag-tagged CYPA. eGFP is used as transfection control. Bottom: identical experiment performed in E6-1 CYPA+/+ control line.

(D) Top: Jurkat CYPA−/− KO cells are transiently transfected with HA-tagged human A3G (HsA3G), Strep-tagged HIV-1 Vif, and Flag-tagged CYPA. eGFP is used as transfection control. Bottom: identical experiment performed in E6-1 CYPA+/+ control line.
(E) MVV Vif activity rescue assay using mutants of CYPA. Strep-tagged MVV Vif, HA-tagged OaA3Z2Z3, and various Flag-tagged CYPA constructs are transfected into Jurkat CYPA−/− KO line, and Vif activity assessed through A3 stability. See also Figures S4, S7.
FIGURE 7. Modular Conservation of CRL Hijacking and Non-Canonical Cofactor Recruitment by Vif
The host CRL complex hijacked by Vif represents a conserved host-pathogen interaction module. Vif proteins recruit non-canonical host cofactors in a lineage-specific manner within the lentivirus genus.